Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-177 pembrolizumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer
jRCT2080223183Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, oxaliplatin, folinic acid, fluorouracil, irinotecan and 2 more in colorectal cancer (CRC) (2 arms), sponsored by Merck & Co. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080223183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223183.